MA47452A - Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer - Google Patents
Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancerInfo
- Publication number
- MA47452A MA47452A MA047452A MA47452A MA47452A MA 47452 A MA47452 A MA 47452A MA 047452 A MA047452 A MA 047452A MA 47452 A MA47452 A MA 47452A MA 47452 A MA47452 A MA 47452A
- Authority
- MA
- Morocco
- Prior art keywords
- heterocyclylsulfonyl
- pyridines
- substitution
- cancer treatment
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762455644P | 2017-02-07 | 2017-02-07 | |
US201762594784P | 2017-12-05 | 2017-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47452A true MA47452A (fr) | 2019-12-18 |
Family
ID=61231287
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047452A MA47452A (fr) | 2017-02-07 | 2018-02-07 | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer |
Country Status (11)
Country | Link |
---|---|
US (1) | US11168069B2 (fr) |
EP (1) | EP3580209A1 (fr) |
JP (1) | JP2020506244A (fr) |
KR (1) | KR20190115012A (fr) |
CN (1) | CN110382480A (fr) |
AU (1) | AU2018218521C1 (fr) |
BR (1) | BR112019016233A2 (fr) |
CA (1) | CA3051538A1 (fr) |
MA (1) | MA47452A (fr) |
MX (1) | MX2019009354A (fr) |
WO (1) | WO2018146471A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
WO2018146468A1 (fr) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines et leur utilisation dans le traitement du cancer |
CN110382486A (zh) | 2017-02-07 | 2019-10-25 | 欧比力克治疗公司 | 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途 |
MX2019009266A (es) | 2017-02-07 | 2019-11-05 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer. |
RU2020126540A (ru) * | 2018-02-12 | 2022-03-14 | Синда Фарма Аб | Ингибиторы тиоредоксинредуктазы для применения для лечения рака |
US20200115389A1 (en) | 2018-09-18 | 2020-04-16 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
KR20240067673A (ko) | 2022-11-09 | 2024-05-17 | 한국생산기술연구원 | 탄소 나노스크롤 및 탄소나노튜브 얀 복합체 기반 케모메카니컬 에너지 하베스터 및 그의 제조 방법 |
KR20240067583A (ko) | 2022-11-09 | 2024-05-17 | 한국생산기술연구원 | 정전압 압전기화학 분석 방법 |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0031173B1 (fr) * | 1979-12-19 | 1983-09-14 | Duphar International Research B.V | Nitrothiophènes, procédé pour leur préparation, ainsi que compositions fongicides et/ou bactéricides les contenant |
US4456469A (en) | 1980-03-07 | 1984-06-26 | E. I. Du Pont De Nemours And Company | Pyridyl sulfone herbicides |
AU543161B2 (en) | 1980-03-07 | 1985-04-04 | E.I. Du Pont De Nemours And Company | Pyrimidine or s.triazine derivatives |
US4791127A (en) | 1985-10-07 | 1988-12-13 | Nippon Kayaku Kabushiki Kaisha | Alkanesulfonate derivatives and their use as insecticides, acaricides or nematicides |
DE3812177A1 (de) | 1988-04-13 | 1989-10-26 | Bayer Ag | 2-phenylsulfinyl-nitro-pyridine, verfahren zu ihrer herstellung und ihre verwendung |
AU2395095A (en) | 1994-04-29 | 1995-11-29 | G.D. Searle & Co. | Method of using (h+/k+) atpase inhibitors as antiviral agents |
DE19531148A1 (de) | 1995-08-24 | 1997-02-27 | Basf Ag | Fungizide Pyridin-2-yl-Derivate |
US6069144A (en) | 1995-08-24 | 2000-05-30 | Basf Aktiengesellschaft | N-heterocyclic compounds, intermediate products used to prepare them, agents containing them and their use in antifungal applications |
US6191280B1 (en) | 1997-05-30 | 2001-02-20 | Basf Aktiengesellschaft | Method for producing substituted thiopyridines |
US6284923B1 (en) | 1997-08-22 | 2001-09-04 | Tularik Inc | Substituted benzene compounds as antiproliferative and cholesterol lowering action |
WO1999018096A1 (fr) | 1997-10-02 | 1999-04-15 | Merck & Co., Inc. | Inhibiteurs de la prenyl-proteine transferase |
US6297239B1 (en) | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
US6191170B1 (en) | 1998-01-13 | 2001-02-20 | Tularik Inc. | Benzenesulfonamides and benzamides as therapeutic agents |
ATE236136T1 (de) | 1998-01-16 | 2003-04-15 | Hoffmann La Roche | Benzosulfonderivate |
WO2001064642A2 (fr) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides et inhibiteurs connexes du facteur xa |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003211427A1 (en) | 2002-02-18 | 2003-09-04 | Ishihara Sangyo Kaisha, Ltd. | Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same |
US20030236287A1 (en) | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
US7037902B2 (en) | 2002-07-03 | 2006-05-02 | Receptron, Inc. | Affinity small molecules for the EPO receptor |
US7915293B2 (en) | 2003-05-30 | 2011-03-29 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
DE602005011279D1 (de) | 2004-06-04 | 2009-01-08 | Arena Pharm Inc | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen |
US20060019967A1 (en) | 2004-07-21 | 2006-01-26 | Su-Ying Wu | SARS CoV main protease inhibitors |
GB0426313D0 (en) | 2004-12-01 | 2005-01-05 | Merck Sharp & Dohme | Therapeutic agents |
WO2006083692A2 (fr) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Procédés d'identification de modulateurs de bromodomaines |
GB0504828D0 (en) | 2005-03-09 | 2005-04-13 | Merck Sharp & Dohme | Therapeutic agents |
US20100048713A1 (en) | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
CA2647338A1 (fr) | 2006-04-28 | 2007-11-08 | Avexa Limited | Inhibiteurs de l'integrase-3 |
EP2061472A4 (fr) * | 2006-05-22 | 2010-12-22 | Thioredoxin Systems Ab | Inhibiteurs de thioredoxine reductase bacterienne et procédés d'utilisation afférents |
BRPI0814423B1 (pt) | 2007-07-17 | 2022-04-19 | Plexxikon, Inc | Compostos que modulam quinase e composição farmacêutica compreendendo os mesmos |
CN101723932B (zh) | 2008-10-31 | 2013-11-20 | 北京以岭生物工程技术有限公司 | 硝基吡啶乙烯亚胺化合物、其药物组合物及其制备方法和用途 |
AU2010253820A1 (en) * | 2009-05-28 | 2011-12-22 | President And Fellows Of Harvard College | N,N-diarylurea compounds and N,N'-diarylthiourea compounds as inhibitors of translation initiation |
EP3205647B1 (fr) | 2009-08-17 | 2020-05-13 | Memorial Sloan-Kettering Cancer Center | Dérivés 2-(pyrimidin-5-yl)-thiopyrimidine en tant que modulateurs hsp70 and hsc70 pour le traitement de maladies proliferatives |
EP2535059A4 (fr) | 2010-02-10 | 2014-03-12 | Public Univ Corp Yokohama City | Utilisation d'un composé se liant à msin3b qui se lie, de façon spécifique, au facteur silenceur de la spécification neuronale nrsf |
EP2536411A4 (fr) * | 2010-02-18 | 2013-08-07 | Univ Princeton | Inhibiteurs du métabolisme d'acide gras à longue et très longue chaîne comme antiviraux à large spectre |
CN102206172B (zh) | 2010-03-30 | 2015-02-25 | 中国医学科学院医药生物技术研究所 | 一组取代双芳基化合物及其制备方法和抗病毒应用 |
EP2609089A1 (fr) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Inhibiteurs sélectifs de la 17-bêta-hydroxystéroïde déshydrogénase de type 1 |
CA2864356A1 (fr) | 2012-02-10 | 2013-08-15 | The Board Of Regents Of The University Of Texas System | Modulateurs de proteines d'echange directement activees par l'ampc (epac) |
WO2015006458A1 (fr) | 2013-07-10 | 2015-01-15 | Boehringer Ingelheim International Gmbh | Nouveaux ligands d'azote-phosphore chiraux et leur utilisation pour l'hydrogénation asymétrique d'alcènes |
CN104672214B (zh) | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
CN105503827B (zh) | 2014-10-11 | 2019-09-24 | 上海翰森生物医药科技有限公司 | Egfr抑制剂及其制备方法和用途 |
CN105085483B (zh) | 2015-06-04 | 2019-01-01 | 湖北生物医药产业技术研究院有限公司 | 激酶抑制剂及其应用 |
CN104987324B (zh) | 2015-06-04 | 2018-05-04 | 湖北生物医药产业技术研究院有限公司 | 作为alk抑制剂的嘧啶衍生物 |
GB201514021D0 (en) | 2015-08-07 | 2015-09-23 | Arner Elias Set Jeno | Novel Pyridines and their use in the treatment of cancer |
CN110382486A (zh) | 2017-02-07 | 2019-10-25 | 欧比力克治疗公司 | 杂芳磺酰基取代的吡啶和其在癌症治疗中的用途 |
WO2018146468A1 (fr) | 2017-02-07 | 2018-08-16 | Oblique Therapeutics Ab | Sulfinylpyridines et leur utilisation dans le traitement du cancer |
MX2019009266A (es) | 2017-02-07 | 2019-11-05 | Oblique Therapeutics Ab | Piridinas sustituidas con hidrocarbilsulfonilo y su uso en el tratamiento del cancer. |
-
2018
- 2018-02-07 WO PCT/GB2018/050345 patent/WO2018146471A1/fr unknown
- 2018-02-07 CN CN201880010203.5A patent/CN110382480A/zh active Pending
- 2018-02-07 CA CA3051538A patent/CA3051538A1/fr active Pending
- 2018-02-07 KR KR1020197024690A patent/KR20190115012A/ko not_active Application Discontinuation
- 2018-02-07 US US16/483,961 patent/US11168069B2/en active Active
- 2018-02-07 AU AU2018218521A patent/AU2018218521C1/en not_active Ceased
- 2018-02-07 BR BR112019016233A patent/BR112019016233A2/pt not_active IP Right Cessation
- 2018-02-07 MA MA047452A patent/MA47452A/fr unknown
- 2018-02-07 JP JP2019563698A patent/JP2020506244A/ja active Pending
- 2018-02-07 MX MX2019009354A patent/MX2019009354A/es unknown
- 2018-02-07 EP EP18705719.5A patent/EP3580209A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US20200024255A1 (en) | 2020-01-23 |
US11168069B2 (en) | 2021-11-09 |
JP2020506244A (ja) | 2020-02-27 |
AU2018218521C1 (en) | 2022-06-09 |
WO2018146471A1 (fr) | 2018-08-16 |
CN110382480A (zh) | 2019-10-25 |
AU2018218521B2 (en) | 2021-11-25 |
RU2019127886A3 (fr) | 2021-05-17 |
RU2019127886A (ru) | 2021-03-10 |
KR20190115012A (ko) | 2019-10-10 |
EP3580209A1 (fr) | 2019-12-18 |
BR112019016233A2 (pt) | 2020-04-07 |
CA3051538A1 (fr) | 2018-08-16 |
AU2018218521A1 (en) | 2019-08-15 |
MX2019009354A (es) | 2019-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA47452A (fr) | Pyridines à substitution hétérocyclylsulfonyle et leur utilisation dans le traitement du cancer | |
MA43163A (fr) | Polypeptides à domaine extracellulaire cd80 et leur utilisation dans le traitement du cancer | |
MA45122A (fr) | Inhibiteurs hétérocycliques de cbp/ep300 et leur utilisation dans le traitement du cancer | |
MA47458A (fr) | Pyridines à substitution hydrocarbylsulfonyle et leur utilisation dans le traitement du cancer | |
MA47451A (fr) | Pyridines à substitution hétéroarylsulfonyle et leur utilisation dans le traitement du cancer | |
MA52886A (fr) | Composés de purinone et leur utilisation dans le traitement du cancer | |
MA42915A (fr) | Pyridines et leur utilisation dans le traitement du cancer | |
MA39960A (fr) | Composés imidazo[4,5c]quinoline-2-one et leur utilisation dans le traitement du cancer | |
CL2017001901A1 (es) | Terapéuticos de glicano y métodos relacionados del mismo | |
DK3294770T4 (da) | Terapeutiske og diagnostiske fremgangsmåder til cancer | |
DK3134125T3 (da) | Antistof-lægemiddel-konjugat og anvendelse deraf til behandling af cancer | |
MA47450A (fr) | Sulfinylpyridines et leur utilisation dans le traitement du cancer | |
HK1245287A1 (zh) | IL13RAα2結合劑和其在癌症治療中的用途 | |
DK3240554T3 (da) | Blautia stercosis og wexlerae til anvendelse til behandling af inflammatoriske og autoimmune sygdomme | |
DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
MA41316A (fr) | Gènes de détermination du sexe et leur utilisation en reproduction | |
DK3416957T3 (da) | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes | |
MA41794A (fr) | Agents thérapeutiques modifiés et compositions associées | |
MA47408A (fr) | Traitement du cancer | |
MA45046A (fr) | Irinotécan nanoliposomal utilisé dans le traitement du cancer bronchique à petites cellules | |
MA43588A (fr) | Protéines de fusion follistatine-fc recombinantes et leur utilisation dans le traitement de la dystrophie musculaire de duchenne | |
DK3325618T3 (da) | Hidtil ukendte trypsin-isoformer og anvendelse deraf | |
MA51823A (fr) | Osimertinib destiné à être utilisé dans le traitement du cancer du poumon non à petites cellules | |
DK3270990T3 (da) | Hængslet skjoldanordning og beslægtede fremgangsmåder | |
DK3258964T3 (da) | Detektion og behandling af maligne tumorer i CNS |